Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.47 |
| ▸ | PPARA | Q07869 | 17/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796001 | 0.89 | PPARG (0.47) | PPARGPPARAPPARDESR1ESR2 | |
| SCHEMBL6804338 | 0.89 | PPARG (0.47) | PPARGPPARAPPARDESR1ESR2 | |
| SCHEMBL6796006 | 0.89 | PPARG (0.47) | PPARGPPARAPPARDESR1ESR2 | |
| SCHEMBL6791705 | 0.84 | PPARG (0.58) | PPARGPPARAPPARD | |
| SCHEMBL6801661 | 0.81 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL6796469 | 0.81 | PPARG (0.61) | PPARGPPARAPPARD | |
| SCHEMBL6797406 | 0.80 | PPARG (0.60) | PPARGPPARAPPARD | |
| SCHEMBL7248833 | 0.79 | ESR2 (0.43) | PPARGPPARAPPARDESR1ESR2 | |
| SCHEMBL7081949 | 0.79 | ESR2 (0.43) | PPARGPPARAPPARDESR1ESR2 | |
| SCHEMBL7081951 | 0.79 | ESR2 (0.43) | PPARGPPARAPPARDESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713508-B2 | SUCH AS 7-(3-(3-TRIFLUOROMETHYL-7-PROPYL-6-BENZ-(4,5)-ISOXAZOLOXY)PROPOXY)-2 -ETHYLCHROMANE-2-CARBOXYLIC ACID WHICH ARE POTENT AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR | MERCK & CO., INC. | 2004-03-30 | — | — | US | disclosed |
| EP-1347755-A2 | BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002060434-A2 | BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20020103242-A1 | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103242-A1 | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.